222 related articles for article (PubMed ID: 36469102)
21. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
22. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Wan Z; Han B
Front Oncol; 2020; 10():579221. PubMed ID: 33117717
[TBL] [Abstract][Full Text] [Related]
23. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
Orazi A; Germing U
Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
[TBL] [Abstract][Full Text] [Related]
24. Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.
Loghavi S; Wang SA
Surg Pathol Clin; 2019 Sep; 12(3):651-669. PubMed ID: 31352979
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
26. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
27. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
Thota S; Gerds AT
Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
[TBL] [Abstract][Full Text] [Related]
29. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
[TBL] [Abstract][Full Text] [Related]
30. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
Mughal TI; Cross NC; Padron E; Tiu RV; Savona M; Malcovati L; Tibes R; Komrokji RS; Kiladjian JJ; Garcia-Manero G; Orazi A; Mesa R; Maciejewski JP; Fenaux P; Itzykson R; Mufti G; Solary E; List AF
Haematologica; 2015 Sep; 100(9):1117-30. PubMed ID: 26341525
[TBL] [Abstract][Full Text] [Related]
31. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Clara JA; Sallman DA; Padron E
Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
[TBL] [Abstract][Full Text] [Related]
32. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
[TBL] [Abstract][Full Text] [Related]
33. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
[TBL] [Abstract][Full Text] [Related]
34. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?
Sangiorgio VFI; Orazi A; Arber DA
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101139. PubMed ID: 32460987
[TBL] [Abstract][Full Text] [Related]
36. Clinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): An Integrative Review.
Prieto-Torres L; Requena L; Rodríguez-Pinilla SM
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136431
[TBL] [Abstract][Full Text] [Related]
37. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
38. JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome.
Krah NM; Miotke L; Li P; Patel JL; Bowen AR; Pomicter AD; Patel AB
J Natl Compr Canc Netw; 2023 Dec; 21(12):1218-1223. PubMed ID: 38081125
[TBL] [Abstract][Full Text] [Related]
39. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
40. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]